Generic Name and Formulations:
Droxidopa 100mg, 200mg, 300mg+; capsules; (+) contains tartrazine.
Indications for NORTHERA:
Symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Swallow whole. Take with or without food. Initially 100mg three times daily in the morning, midday, and late afternoon (≥3hrs prior to bedtime). Titrate in increments of 100mg three times daily every 24–48hrs; max 600mg three times daily.
May cause or exacerbate supine hypertension. Monitor BP (supine and head-elevated sleeping positions) prior to initiating and after increasing the dose; reduce dose or discontinue if supine hypertension persists. Monitor for symptoms of neuroleptic malignant syndrome; observe carefully during dose changes or when concomitant levodopa is reduced abruptly or discontinued, especially if receiving neuroleptics. May exacerbate ischemic heart disease, arrhythmias, CHF. Discontinue if hypersensitivity reactions occur. Allergic reactions (tartrazine). Reevaluate periodically. Severe renal impairment (GFR <30mL/min): limited data. Pregnancy. Nursing mothers: not recommended.
Concomitant drugs that increase BP (eg, norepinephrine, ephedrine, midodrine, and triptans); increased risk of supine hypertension. Concomitant dopa-decarboxylase inhibitors: may need to adjust droxidopa dose. Avoid concomitant non-selective MAOIs or linezolid.
Headache, dizziness, nausea, hypertension, falls, UTI, syncope; hyperpyrexia, confusion.
Sign Up for Free e-newsletters
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- Handling Chemotherapy Premedications
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|